News | June 13, 2023
Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule
UTD2 is the world's first oral epothilone microtubule inhibitor
UTD2 is the world's first oral epothilone microtubule inhibitor
The new lab will enable the Group to accelerate its efforts in this area, building new competencies and capabilities, as well as strengthening Solvay’s ability to develop breakthroughs in biodegradable-by-design solutions.
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
The EU certification will support supplies of drug products registered in Europe, from this manufacturing site
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
Health Secretary highlights the need for capacity building programmes for Medical Officers to tackle Non Communicable Diseases at the primary level
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
Subscribe To Our Newsletter & Stay Updated
